Retraction
Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma
Paper Information
Record ID:
46949
Author(s):
Journal:
Publication Date:
October 13, 2014
Retraction Date:
August 11, 2023
(2.3 years years ago)
Subjects:
Institutions:
- Peter MacCallum Cancer Centre, East Melbourne
- University of Melbourne, Parkville, Victoria
- Queensland Institute of Medical Research
- School of Medicine, University of Queensland, Herston, Queensland, Australia
- Juntendo University School of Medicine, Tokyo, Japan
- Peter MacCallum Cancer Centre, East Melbourne
- University of Melbourne, Parkville, Victoria
Countries:
Article Type:
Publisher:
American Society of Clinical Oncology
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1200/JCO.23.01358Additional Notes:
Mark J Smyth has institutional finding of misconduct;
Citations (74)
74
Total Citations7
Post-Retraction(9.5%)
67
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
5
Within 1 year
0
After 2+ years
509
Days since retraction (latest)
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
Yenny Angela, Sebastian Haferkamp, Carsten Weishaupt et al. (9 authors)
Cancer Immunology Immunotherapy
Open Access
Published: Jun 2019
52 citations
52 citations
1522 days before retraction
Clinical Impact of RANK Signalling in Ovarian Cancer
Verena Wieser, Susanne Sprung, Irina Tsibulak et al. (8 authors)
Cancers
Open Access
Published: Jun 2019
15 citations
15 citations
1525 days before retraction
Pulling RANK on Cancer: Blocking Aire-Mediated Central Tolerance to Enhance Immunotherapy
Maureen A. Su, Mark S. Anderson
Cancer Immunology Research
Open Access
Published: Jun 2019
15 citations
15 citations
1532 days before retraction
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
Roger von Moos, Luís Costa, Eva González‐Suárez et al. (6 authors)
Cancer Treatment Reviews
Open Access
Published: May 2019
118 citations
118 citations
1549 days before retraction
RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review
Peter A. van Dam, Yannick Verhoeven, Julie Jacobs et al. (14 authors)
International Journal of Molecular Sciences
Open Access
Published: May 2019
26 citations
26 citations
1562 days before retraction
The RANK–RANKL axis: an opportunity for drug repurposing in cancer?
Solange Peters, Philippe Clézardin, Iván Márquez‐Rodas et al. (5 authors)
Clinical & Translational Oncology
Open Access
Published: Jan 2019
38 citations
38 citations
1667 days before retraction
Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis
Y. Nakai, Kazuo Okamoto, Asuka Terashima et al. (8 authors)
Bone Research
Open Access
Published: Jan 2019
97 citations
97 citations
1682 days before retraction
The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis — possible applications of anti-RANKL antibody to the treatment of cancer patients
Hisataka Yasuda
Folia Pharmacologica Japonica
Open Access
Published: Jan 2019
6 citations
6 citations
1683 days before retraction
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment
Peter A. van Dam, Yannick Verhoeven, Xuan Bich Trinh et al. (9 authors)
Critical Reviews in Oncology/Hematology
Open Access
Published: Nov 2018
66 citations
66 citations
1743 days before retraction
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Elizabeth Ahern, Mark J. Smyth, William C. Dougall et al. (4 authors)
Nature Reviews Clinical Oncology
Published: Sep 2018
90 citations
90 citations
1787 days before retraction
An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer
Alexander Liede, Rohini K. Hernandez, Sally Wade et al. (8 authors)
OncoImmunology
Open Access
Published: Jun 2018
63 citations
63 citations
1872 days before retraction
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
Muhammad Zubair Afzal, Keisuke Shirai
Melanoma Research
Published: May 2018
34 citations
34 citations
1919 days before retraction
Faculty Opinions recommendation of Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Sakae Tanaka
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Open Access
Published: May 2018
1928 days before retraction
Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy
Sébastien S. Dufresne, Antoine Boulanger‐Piette, Sabrina Bossé et al. (12 authors)
Acta Neuropathologica Communications
Open Access
Published: Apr 2018
53 citations
53 citations
1935 days before retraction
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao, Wei Yang, Yuanyuan Huang et al. (6 authors)
Cellular Physiology and Biochemistry
Open Access
Published: Jan 2018
162 citations
162 citations
2048 days before retraction
The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review
A. Groot, Natasha M. Appelman‐Dijkstra, Sjoerd H. van der Burg et al. (4 authors)
Cancer Treatment Reviews
Open Access
Published: Nov 2017
110 citations
110 citations
2108 days before retraction
RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?
Carlo Resteghini, Salvatore Alfieri, Pasquale Quattrone et al. (13 authors)
Oncotarget
Open Access
Published: Oct 2017
5 citations
5 citations
2125 days before retraction
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity
Pearl Bakhru, Menglei Zhu, Hsing‐Hui Wang et al. (17 authors)
JCI Insight
Open Access
Published: Sep 2017
42 citations
42 citations
2151 days before retraction
Complications of bone metastases from malignant melanoma
Jamal Zekri, Maria Marples, Dominic Taylor et al. (6 authors)
Journal of bone oncology
Open Access
Published: Aug 2017
33 citations
33 citations
2184 days before retraction
Osteoclast-Like Giant Cells in Malignant Melanoma: Unintentional Accident or Strategic Recruitment?
Xiaoxiao Li, Stephanie Savory, Travis Vandergriff et al. (4 authors)
American Journal of Dermatopathology
Published: Jul 2017
4 citations
4 citations
2225 days before retraction
Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice
Elizabeth Ahern, Heidi Harjunpää, Deborah S. Barkauskas et al. (10 authors)
Clinical Cancer Research
Open Access
Published: Jun 2017
79 citations
79 citations
2242 days before retraction
Paper citing Combination Anti-CTLA-4 and Anti-RANKL in Metastat...
Unknown Authors
Unknown Journal
Published: Jan 2017
2413 days before retraction
Cancer immunotherapy
Stephanie A. Mullane, Joaquim Bellmunt
Current Opinion in Urology
Published: Aug 2016
5 citations
5 citations
2536 days before retraction
<scp>RANK</scp> as a therapeutic target in cancer
Eva González‐Suárez, Adrián Sanz‐Moreno
FEBS Journal
Open Access
Published: Jan 2016
52 citations
52 citations
2770 days before retraction
Quick Stats
Total Citations:
74
Years Since Retraction:
2.3 years
Open Access:
Yes
Last Checked:
Jul 24, 2025